Carboplatin with intravenous and subsequent oral administration
of vinorelbine in resected non-small-cell-lung cancer in
real-world setup

J 2017

Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world setup

KOLEK, Vítězslav, Ivona GRAGÁRKOVÁ, Leona KOUBKOVÁ, Jana SKŘIČKOVÁ, Jiřina ŠVECOVÁ et. al.

Základní údaje

Originální název

Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world setup

Autoři

KOLEK, Vítězslav, Ivona GRAGÁRKOVÁ, Leona KOUBKOVÁ, Jana SKŘIČKOVÁ, Jiřina ŠVECOVÁ, Dimka SIXTOVÁ, Jiří BARTOŠ a Aleš TICHOPÁD

Vydání

Plos One, San Francisco, Public Library of Science, 2017, 1932-6203

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.766

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1371/journal.pone.0181803

UT WoS

000406643100063

Klíčová slova anglicky

Carboplatin; vinorelbine; non-small-cell-lung cancer

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 4. 2018 19:12, Soňa Böhmová

Anotace

V originále

Objectives Adjuvant cisplatin-based chemotherapy is recommended for routine use in patients with Stage IIA, IIB or IIIA non-small cell lung cancer (NSCLC) after complete resection. Results obtained for Stage IB were not conclusive. While vinorelbine plus cisplatin is the preferred choice after resection, combining vinorelbine with carboplatin promises improved compliance and delivery of drugs due to lower toxicity. We evaluated the impact of this option on treatment compliance and survival under real-world conditions. Material and methods A prospective, single-arm, multicenter, non-interventional study evaluated the tolerability, dose intensity and survival resulting from adjuvant use of intravenous carboplatin (AUC 5 on day 1) with vinorelbine administered both intravenously (25 mg/m2 on day 1) and orally (60 mg/m2 on day 8) within four cycles of 21 days each. A total of 74 patients with a median age of 64 years were observed. Results The mean number of accomplished cycles was 3.78, and 62 patients (83.7%) completed all four planned cycles. Relative dose intensity for carboplatin was 88.9%, for intravenous vinorelbine 93.1%, and for oral vinorelbine 83.2%. Median follow-up was 4.73 years. Median disease-specific survival (DSS) was 7.63 years, median overall survival (OS) was 5.90 years, median disease-free survival (DFS0) was 4.43 years, and five-year survival was 56.2%. TNM stage of disease significantly affected DSS and OS. Favorable survival was observed in females, nonsmokers, patients aged over 65 years, patient with prior lobectomy, patients with tumor of squamous histology, and those who finished the planned therapy, but the differences were non-significant. Conclusion Adjuvant carboplatin with vinorelbine switched from intravenous to oral administration was shown to be a favorable regimen with regard to tolerability and safety. Compliance to therapy was high, and survival parameters were promising, showing that applied regimen can be another potential option for adjuvant chemotherapy in patients with NSCLC.

Citovat

KOLEK, Vítězslav, Ivona GRAGÁRKOVÁ, Leona KOUBKOVÁ, Jana SKŘIČKOVÁ, Jiřina ŠVECOVÁ, Dimka SIXTOVÁ, Jiří BARTOŠ a Aleš TICHOPÁD. Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world setup. Plos One. San Francisco: Public Library of Science, 2017, roč. 12, č. 7, s. 1-13. ISSN 1932-6203. Dostupné z: https://dx.doi.org/10.1371/journal.pone.0181803.

@article{1387486,
   author = {Kolek, Vítězslav and Gragárková, Ivona and Koubková, Leona and Skřičková, Jana and Švecová, Jiřina and Sixtová, Dimka and Bartoš, Jiří and Tichopád, Aleš},
   article_location = {San Francisco},
   article_number = {7},
   doi = {http://dx.doi.org/10.1371/journal.pone.0181803},
   keywords = {Carboplatin; vinorelbine; non-small-cell-lung cancer},
   language = {eng},
   issn = {1932-6203},
   journal = {Plos One},
   title = {Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world setup},
   url = {http://dx.doi.org/10.1371/journal.pone.0181803},
   volume = {12},
   year = {2017}
}

TY  - JOUR
ID  - 1387486
AU  - Kolek, Vítězslav - Gragárková, Ivona - Koubková, Leona - Skřičková, Jana - Švecová, Jiřina - Sixtová, Dimka - Bartoš, Jiří - Tichopád, Aleš
PY  - 2017
TI  - Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world setup
JF  - Plos One
VL  - 12
IS  - 7
SP  - 1-13
EP  - 1-13
PB  - Public Library of Science
SN  - 19326203
KW  - Carboplatin
KW  - vinorelbine
KW  - non-small-cell-lung cancer
UR  - http://dx.doi.org/10.1371/journal.pone.0181803
L2  - http://dx.doi.org/10.1371/journal.pone.0181803
N2  - Objectives Adjuvant cisplatin-based chemotherapy is recommended for routine use in patients with Stage IIA, IIB or IIIA non-small cell lung cancer (NSCLC) after complete resection. Results obtained for Stage IB were not conclusive. While vinorelbine plus cisplatin is the preferred choice after resection, combining vinorelbine with carboplatin promises improved compliance and delivery of drugs due to lower toxicity. We evaluated the impact of this option on treatment compliance and survival under real-world conditions. Material and methods A prospective, single-arm, multicenter, non-interventional study evaluated the tolerability, dose intensity and survival resulting from adjuvant use of intravenous carboplatin (AUC 5 on day 1) with vinorelbine administered both intravenously (25 mg/m2 on day 1) and orally (60 mg/m2 on day 8) within four cycles of 21 days each. A total of 74 patients with a median age of 64 years were observed. Results The mean number of accomplished cycles was 3.78, and 62 patients (83.7%) completed all four planned cycles. Relative dose intensity for carboplatin was 88.9%, for intravenous vinorelbine 93.1%, and for oral vinorelbine 83.2%. Median follow-up was 4.73 years. Median disease-specific survival (DSS) was 7.63 years, median overall survival (OS) was 5.90 years, median disease-free survival (DFS0) was 4.43 years, and five-year survival was 56.2%. TNM stage of disease significantly affected DSS and OS. Favorable survival was observed in females, nonsmokers, patients aged over 65 years, patient with prior lobectomy, patients with tumor of squamous histology, and those who finished the planned therapy, but the differences were non-significant. Conclusion Adjuvant carboplatin with vinorelbine switched from intravenous to oral administration was shown to be a favorable regimen with regard to tolerability and safety. Compliance to therapy was high, and survival parameters were promising, showing that applied regimen can be another potential option for adjuvant chemotherapy in patients with NSCLC.
ER  -

KOLEK, Vítězslav, Ivona GRAGÁRKOVÁ, Leona KOUBKOVÁ, Jana SKŘIČKOVÁ, Jiřina ŠVECOVÁ, Dimka SIXTOVÁ, Jiří BARTOŠ a Aleš TICHOPÁD. Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world setup. \textit{Plos One}. San Francisco: Public Library of Science, 2017, roč.~12, č.~7, s.~1-13. ISSN~1932-6203. Dostupné z: https://dx.doi.org/10.1371/journal.pone.0181803.

Podrobný výpis o publikaci